메뉴 건너뛰기




Volumn 32, Issue SUPPL. 1, 2002, Pages 29-32

Economic impact of treating inhibitor patients

Author keywords

Cost; Inhibitors; QALY; rFVIIa

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; ALLOANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

EID: 1042287913     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057298     Document Type: Conference Paper
Times cited : (11)

References (10)
  • 1
    • 0034995507 scopus 로고    scopus 로고
    • Developing guidance for budget impact analysis
    • Trueman P, Drummond M, Hutton J: Developing Guidance for Budget Impact Analysis. Pharmacoeconomics 2001;19:609-621.
    • (2001) Pharmacoeconomics , vol.19 , pp. 609-621
    • Trueman, P.1    Drummond, M.2    Hutton, J.3
  • 3
    • 0032252398 scopus 로고    scopus 로고
    • Pharmaco-economic aspects of inhibitor treatment
    • Goudemand J: Pharmaco-economic aspects of inhibitor treatment. Eur J Haematol 1998; 61(suppl 63):24-27.
    • (1998) Eur J Haematol , vol.61 , Issue.SUPPL. 63 , pp. 24-27
    • Goudemand, J.1
  • 4
    • 0033220609 scopus 로고    scopus 로고
    • Treatment of patients with inhibitors: Cost issues
    • Goudemand J: Treatment of patients with inhibitors: Cost issues. Haemophilia 1999;5: 397-401.
    • (1999) Haemophilia , vol.5 , pp. 397-401
    • Goudemand, J.1
  • 5
    • 0003984065 scopus 로고    scopus 로고
    • COCIS (cost of care inhibitor study): Evaluation of the socio-economic impact of inhibitors in haemophiliacs
    • Presented at the World Federation of Hemophilia MTG, July 2000
    • Gringeri A, Mantovani G, Santagostino E et al: COCIS (cost of care inhibitor study): Evaluation of the socio-economic impact of inhibitors in haemophiliacs. Presented at the World Federation of Hemophilia MTG, July 2000. Haemophilia 2000;6:441.
    • (2000) Haemophilia , vol.6 , pp. 441
    • Gringeri, A.1    Mantovani, G.2    Santagostino, E.3
  • 6
    • 0031788226 scopus 로고    scopus 로고
    • Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an antifactor VIII inhibitor
    • Stewart AJ, Hanley JP, Ludlam CA: Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an antifactor VIII inhibitor. Blood Coagulation and Fibrinolysis 1998;9(suppl 1):593-595.
    • (1998) Blood Coagulation and Fibrinolysis , vol.9 , Issue.SUPPL. 1 , pp. 593-595
    • Stewart, A.J.1    Hanley, J.P.2    Ludlam, C.A.3
  • 8
    • 24744470813 scopus 로고    scopus 로고
    • Economic impact of recombinant activated factor VII compared to activated prothrombin-complex concentrate in the hospital treatment of a mild to moderate bleed among adult haemophilia patients with inhibitors in the UK
    • in press
    • Odeyemi IAO, Guest JF: Economic impact of recombinant activated factor VII compared to activated prothrombin-complex concentrate in the hospital treatment of a mild to moderate bleed among adult haemophilia patients with inhibitors in the UK. Pharmacoeconomics 2001, in press.
    • (2001) Pharmacoeconomics
    • Odeyemi, I.A.O.1    Guest, J.F.2
  • 9
    • 24744441573 scopus 로고    scopus 로고
    • Economic impact of recombinant activated factor VII compared with activated prothrombin-complex concentrate in the home treatment of minor bleed in adult haemophilia patients with high titre high responding inhibitors to coagulation factors VIII and IX
    • San Francisco, Dec (abstract)
    • Odeyemi IAO, Guest JF: Economic impact of recombinant activated factor VII compared with activated prothrombin-complex concentrate in the home treatment of minor bleed in adult haemophilia patients with high titre high responding inhibitors to coagulation factors VIII and IX. Presented at the 2000 Annual Meeting of the American Society of Hematology, San Francisco, Dec 2000 (abstract).
    • (2000) 2000 Annual Meeting of the American Society of Hematology
    • Odeyemi, I.A.O.1    Guest, J.F.2
  • 10
    • 0034998671 scopus 로고    scopus 로고
    • Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX
    • Ekert H, Brewin T, Boey W, Davey P, Tilden D: Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX. Haemophilia 2001;7:279-285.
    • (2001) Haemophilia , vol.7 , pp. 279-285
    • Ekert, H.1    Brewin, T.2    Boey, W.3    Davey, P.4    Tilden, D.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.